Results 11 to 20 of about 4,368,468 (230)

Autophagy: A new strategy for host-directed therapy of tuberculosis

Virulence, 2019
Tuberculosis (TB), which is primarily caused by the major etiologic agent Mycobacterium tuberculosis (Mtb), remains a serious infectious disease worldwide.
Seungwha Paik, Jin Kyung Kim, Chaeuk Chung, Eun-Kyeong Jo   +3 more
doaj   +3 more sources

Host-directed therapy in diabetes and tuberculosis comorbidity toward global tuberculosis elimination [PDF]

International Journal of Infectious Diseases
Host-directed therapy could potentially revolutionize tuberculosis control as an adjunct to traditional antibiotics for the treatment of tuberculosis disease and as a strategy to prevent disease progression following Mycobacterium tuberculosis infection.
Steven G. Smith, Ruth Bowness, Jacqueline M. Cliff   +2 more
doaj   +4 more sources

Metformin as Host-Directed Therapy for TB Treatment: Scoping Review [PDF]

Frontiers in Microbiology, 2020
Tuberculosis (TB) disease is an international health concern caused by the bacteria Mycobacterium tuberculosis (Mtb). Evolution of multi-drug-resistant strains may cause bacterial persistence, rendering existing antibiotics ineffective.
Nikita Naicker, Alex Sigal, Alex Sigal, Alex Sigal, Kogieleum Naidoo, Kogieleum Naidoo   +5 more
doaj   +2 more sources

Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis [PDF]

Nature Communications
Mycobacterium tuberculosis establishes within host cells by inducing anti-apoptotic Bcl-2 family proteins, triggering necrosis, inflammation, and fibrosis.
Medha Singh, Mona O. Sarhan, Nerketa N. L. Damiba, Alok K. Singh, Andres Villabona-Rueda, Oscar J. Nino-Meza, Xueyi Chen, Yuderleys Masias-Leon, Carlos E. Ruiz-Gonzalez, Alvaro A. Ordonez, Franco R. D’Alessio, Eric O. Aboagye, Laurence S. Carroll, Sanjay K. Jain   +13 more
doaj   +2 more sources

Advancing host-directed therapy for tuberculosis: new therapeutic insights from the Toxoplasma gondii

Microbial Cell, 2017
Tuberculosis (TB) drug-development strategies, a wide range of candidate host-directed therapies (HDT)s-including new and repurposed drugs, biologics, and cellular therapies-have been proposed to accelerate eradication of infection and overcome the ...
Chul-Su Yang
doaj   +2 more sources

Repurposing Saquinavir for Host-Directed Therapy to Control Mycobacterium Tuberculosis Infection [PDF]

Frontiers in Immunology, 2021
Despite the available antibiotics, tuberculosis (TB) has made its return since the 90’s of the last century as a global threat mostly due to co-infection with HIV, to the emergence of drug resistant strains and the lack of an effective vaccine.
David Pires, Sofia Valente, Marta Calado, Manoj Mandal, José Miguel Azevedo-Pereira, Elsa Anes   +5 more
doaj   +2 more sources

Relevance of the Warburg Effect in Tuberculosis for Host-Directed Therapy [PDF]

Frontiers in Cellular and Infection Microbiology, 2020
Tuberculosis (TB) was responsible for more deaths in 2019 than any other infectious agent. This epidemic is exacerbated by the ongoing development of multi-drug resistance and HIV co-infection.
Bridgette M. Cumming, Hayden T. Pacl, Adrie J. C. Steyn, Adrie J. C. Steyn, Adrie J. C. Steyn   +4 more
doaj   +2 more sources

Host-directed therapies for tackling multi-drug resistant tuberculosis : learning from the pasteur-bechamp debates [PDF]

, 2015
Tuberculosis remains a global emergency causing an estimated 1.5 million deaths annually. For several decades the major focus of tuberculosis treatment has been on antibiotic development targeting Mycobacterium tuberculosis.
Abdulla, S, Cardona, P-J, Grobusch, MP, Mboko, L, Gant, V, Mayosi, B, Zumla, A, Mandansein, R, Reither, K, Mwaba, P, Nyirenda, T, Garcia-Basteiro, AL, Bates, M, Ippolito, G, Munderi, P, Singh, N, Schito, M, Dieye, TN, Diarra, B, Kaleebu, P, Aseffa, A, Tientcheu, L, Corrah, T, Mulenga, M, Parida, S, Kaufmann, SHE, Macete, E, Noursadeghi, M, Petersen, E, Vilaplana, C, Rakotosamimanana, N, Yeboah-Manu, D, Rustomjee, R, Wejse, C, Martinson, N, Elkington, P, McHugh, TD, Oliver, M, Russell, JBW, Host-Directed Therapies Network Consortium,, Wallis, RS, Sanne, I, Chakaya, J, Bonnet, M, Antonio, M, Padayatchi, N, Sheikh, A, Maeurer, Markus, Host-Directed Therapies Network (HDT-NET) Consortium, ., Rasolofo, V, Kibiki, G, Zumla, A., Maeurer, M, Churchyard, G, Maiga, A, Aklillu, E, Ramjee, G, Mfinanga, E, Hoelscher, M, Steyn, AJC, Ntoumi, F, Edwards, S, Kapata, N, Gagneux, S, Menendez, C, Zumla, Alimuddin, Maeurer, M., Craig, G, Mfinanga, S, Wilkinson, RJ   +69 more
core   +8 more sources

Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles. [PDF]

Int J Pharm, 2022
Khoza LJ, Kumar P, Dube A, Demana PH, Choonara YE.   +4 more
europepmc   +2 more sources

mTORC1 inhibitors rapamycin and everolimus as host-directed therapy for tuberculosis [PDF]

Infection and Immunity
Robin H. G. A. van den Biggelaar, Tom H. M. Ottenhoff   +1 more
doaj   +2 more sources